Research monograph · copper-free edr short-peptide bioregulator (glu-asp-arg tripeptide)
Cognitive Peptide Studies
This monograph collects what the published literature reports about Pinealon — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Published work focuses on neuronal survival under oxidative and hypoxic stress, with cognitive endpoints measured in animal models rather than in humans.
For laboratory research use only — not for human or animal use
Mechanisms
Gene-Level Bioregulation
Described as interacting with DNA directly and altering transcription, which places it in the same short-peptide bioregulator class as Epithalon rather than among receptor ligands.
Reactive Oxygen Species Suppression
Neuronal culture work reports reduced ROS accumulation under oxidative challenge — the mechanism proposed for the survival endpoints measured alongside it.
Neuroprotection & Plasticity
Hypoxia and oxidative-stress models measure neuron survival. Cognitive endpoints are reported in animals; the human literature is thin.
Studied applications
ROS accumulation and neuron survival are measured together in culture under oxidative challenge.
Khavinson et al. 2011
Prenatal hypoxia models measure developmental outcomes, a design specific to this compound's literature.
Arutjunyan et al. 2012
Direct DNA interaction is the proposed mechanism, placing it among short-peptide bioregulators rather than receptor ligands.
Khavinson et al. 2021
Survival under low oxygen is the endpoint, measured in both cell culture and whole animals.
Kozina et al. 2008
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Sequence | L-Glutamyl-L-Aspartyl-L-Arginine (EDR tripeptide) |
|---|---|
| Molecular weight | 418.40 g/mol |
| Molecular formula | C₁₅H₂₆N₆O₈ |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| Available sizes | 10mg |
FAQ
Pinealon is a tripeptide from the same Soviet-era pineal research programme that produced Epithalon. Published work focuses on neuronal survival under oxidative and hypoxic stress, with cognitive endpoints measured in animal models rather than in humans.
Published research on Pinealon concentrates on Neuroprotection & Oxidative Stress, Prenatal Neuroprotection Models, Peptide–Gene Expression and Hypoxia Resistance. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes Pinealon acting across Gene-Level Bioregulation, Reactive Oxygen Species Suppression and Neuroprotection & Plasticity, reported respectively as Peptide–DNA Interaction, Oxidative Stress and Neurotrophic Support. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
Pinealon has a molecular formula of C15H26N6O8, an average mass of 418.4 g/mol and the sequence L-Glutamyl-L-Aspartyl-L-Arginine (EDR tripeptide). It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Pinealon is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. Pinealon is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
